New Study Demonstrates the Ability of Prolaris® to Predict Which Men With Prostate Cancer Will Benefit from Multi-Modality Therapy Clinical Study… Continue Reading

New Studies Demonstrate the Predictive Value of the Vectra® Test in People Diagnosed with Rheumatoid Arthritis Vectra Test Predicts Radiographic Progression… Continue Reading

Myriad Genetics Announces Multiple Presentations at the 2019 American College of Rheumatology Annual Meeting SALT LAKE CITY, Nov. 01, 2019 (GLOBE… Continue Reading

Myriad Genetics to Present Seven Studies at the 2019 National Society of Genetic Counselors Annual Meeting SALT LAKE CITY, Oct. 28,… Continue Reading

Myriad Genetics to Present Five Studies at the 2019 American Society of Human Genetics Annual Meeting SALT LAKE CITY, Oct. 08,… Continue Reading

Myriad Announces Research Collaboration with University of Leeds Clinical Utility Study will Evaluate the Prolaris® Test in Men with Prostate Cancer… Continue Reading

Prolaris® Test Identifies Men with Prostate Cancer Who Can Safely Defer Treatment 65 Percent of Patients Remained on Active Surveillance for… Continue Reading

Myriad Applauds the U.S. Preventive Services Task Force Recommendation on BRCA-Related Cancer Prevention More Women May Benefit from Hereditary Cancer Risk Assessment… Continue Reading

Myriad Will Seek FDA Approval of BRACAnalysis CDx® As a Companion Diagnostic for Lynparza® (olaparib) In Men with Metastatic Castrate-Resistant Prostate… Continue Reading

Prolaris® Test Accurately Predicts Risk of Metastasis in Men Diagnosed with Localized Prostate Cancer Validation Study Shows Prolaris Test Identifies Men… Continue Reading